COMP <GO>
HRMY vs HCM // FREE CASH FLOW YIELD
Harmony Biosciences Holdings Inc. (NASDAQ) VS. HUTCHMED (China) Limited (NASDAQ) • 15-METRIC TALLY: HRMY 7
— HCM 3
▲ FREE CASH FLOW YIELD LEADER: HRMY
LAST: $37.91 (-2.19%) • MKT CAP: $2.26B
fcf-yield
15.48%
LAST: $13.27 (+0.91%) • MKT CAP: $2.29B
fcf-yield
-3.32%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. HCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | HCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | -2.50% | +65.50 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 15.48% | -3.32% | +18.80 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | -7.10% | +31.10 | HRMY | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 68.00% | -49.70 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | -13.00% | +34.50 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 3.63 | +1.75 | HRMY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 42.4 | +8.70 | HRMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 4.8x | +7.10 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.26B | $2.29B | -$37.0M | HCM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | HCM REV | HRMY GROSS % | HCM GROSS % | HRMY FCF | HCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $548.5M | 77.2% | 38.7% | $347.9M | -$78.8M |
| FY 2024 | $714.7M | $630.2M | 78.1% | 44.6% | $218.7M | -$17.4M |
| FY 2023 | $582.0M | $838.0M | — | — | $219.4M | $219.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
HCM // BETA —